Skip to main content

Drug–Drug Interactions Still High in the Medical ICU


June 11, 2012 — Drug–drug interactions (DDIs) are frequent occurrences in the medical intensive care unit (MICU). The severity of the condition and the drug combinations used in the MICU are distinct from those of the DDIs published in other ICU settings (eg, cardiac ICU). Prevention of these DDIs is an important aspect of patient safety.
Pamela L. Smithburger, PharmD, from the Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pennsylvania, and colleagues presented the results of a 4-week, prospective, observational study in an article published online June 7 in the International Journal of Pharmacy Practice. This is the first study that evaluates drug interactions specifically in a MICU population with a variety of diagnoses and comorbid disease states. The authors conclude with the suggestion that patient characteristics and location should be considered when developing a DDI alerting system.
The study included 240 patient evaluations. Two interaction databases (Micromedex and Lexi-Interact) were used to identify DDIs and assign a severity rating to the identified DDIs. Of 457 DDIs identified, roughly 25% (114/457) were considered to be major interactions per at least 1 of the databases used. The rate of DDIs was 190.4/100 patients, and the most commonly involved medications were antihypertensive and anticoagulant/antiplatelet agents.
In accordance with requirements of the institutional review board and the health insurance portability and accountability act, the study did not collect patient identifiers, meaning that clinical outcomes could not be followed over time. Other limitations included lack of generalizability; the academic institution where the evaluation took place had particularly ill MICU patients as a result of transfers from community hospitals and also housed many posttransplant patients.
The authors identified 3 possible reasons for overlooking DDIs in the presence of an alerting system: pharmacist alert fatigue, judgment of an appropriate risk–benefit ratio for the patient receiving the interacting drugs, or clinical decision support software (CDSS) that did not include the DDIs identified by the drug interaction databases used in this study. The authors emphasize that use of computerized physician order entry and CDSS in the ICU setting should provide practitioners with a way to use technology at the point of order entry.
The authors also note that studies in cardiac ICUs have identified more DDIs per 100 patient days than were identified in this study. Moreover, a previously published study conducted in a mixed ICU found that 70% of patients had a DDI during the study period.
Altogether, these studies underscore the fact that drug interaction compendia need to be improved to better identify and guide clinical decision-making.
The authors have disclosed no relevant financial relationships.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volum...
Post a Comment
Read more

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n...
4 comments
Read more